Schering-Plough has selected Huya to identify and present to Schering-Plough on an exclusive basis proprietary lead, preclinical and clinical drug candidates in specific therapeutic areas that originate in China.
Schering-Plough will gain access to Huya’s Chinese bioscience network comprising premier universities, government research institutions and bioparks throughout the country.
Huya already has agreements in place with several of these organizations whereby Huya has ongoing exclusive access to compounds and biologics in a variety of indications. The company is currently evaluating and following the progress of more than 500 drug development candidates.
Huya currently has two Chinese drugs undergoing preclinical development in the US – HBI-3000 and HBI-8000. Both drugs, for cardiac fibrillation and oncology, respectively, have successfully passed US FDA pre-investigational new drug consultations.
Mirielle Gingras, president and CEO of Huya, said: “Our agreement with Schering-Plough demonstrates both the effectiveness of our network in China, and our ability to leverage that network to benefit major development partners in the West. We are delighted to be forging this new alliance, and look forward to a fruitful collaboration.”